The diagnosis of chronic myeloid leukemia is usually established by chromosomal analysis to detect t(9;22)(q34;q11) and RT-PCR to detect BCR-ABL fusion genes, as well as bone marrow and peripheral blood tests with typical manifestations of chronic myeloid leukemia.
The treatment of chronic myeloid leukemia is still based on imatinib mesylate as the first-line therapy, and most patients can achieve complete remission and long-term stability. The problem is that imatinib mesylate is expensive and clinical studies to date have shown that it cannot be discontinued and that the majority of patients will relapse after discontinuation of the drug.
Therefore, allogeneic HSCT is also an ideal treatment for young patients with a suitable donor. Allogeneic HSCT is currently the only treatment that can cure chronic myeloid leukemia.
The specific treatment to be chosen should be discussed in depth with the patient’s physician and carefully selected based on the patient’s age, physical condition, financial condition, disease, availability of donor source and previous treatment history. However, both drug therapy and hematopoietic stem cell transplantation should be performed as early as possible.